Advertisement

Ersttrimesterscreening

  • K.-O. Kagan
  • H. Abele
  • M. Hoopmann

Zusammenfassung

Das Ersttrimesterscreening hat sich in den vergangenen Jahren dramatisch verändert. War es zu Beginn nur als Screeningtest für Trisomie 21 gedacht, ist es heute eine umfassende Risikoanalyse für zahlreiche Komplikationen in der Schwangerschaft. So können heute im Rahmen des Ersttrimesterscreenings etwa die Hälfte aller Fehlbildungen erkannt und die Risiken für Präeklampsie, Frühgeburt und zahlreiche weitere Schwangerschaftskomplikationen ermittelt werden. Das eigentliche kombinierte Screening auf Trisomie 21 basierend auf dem mütterlichem Altersrisiko, der fetalen Nackentransparenz und den Serummarkern freies beta-hCG und PAPP-A rückt dabei in den Hintergrund und wurde in den vergangenen Jahren zunehmend durch die zellfreie DNA-Analyse aus dem mütterlichen Blut abgelöst.

Literatur

  1. Abele H, Wagner N, Hoopmann M, Grischke EM, Wallwiener D, Kagan KO (2010) Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol 35: 525–529Google Scholar
  2. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31: 66–74Google Scholar
  3. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH (2013) Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33: 8–15Google Scholar
  4. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F (2015) Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 45: 16–26Google Scholar
  5. Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH (2013) Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 41: 26–32Google Scholar
  6. Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH (2005) Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 26: 154–157Google Scholar
  7. Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11–13 weeks. Prenat Diagn 31: 75–83Google Scholar
  8. Bilardo CM, Muller MA, Pajkrt E, Clur SA, van Zalen M, Bijlsma EK (2007) Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 30: 11–18Google Scholar
  9. Bilardo CM, Timmerman E, Pajkrt E, van Maarle M (2010) Increased nuchal translucency in euploid fetuses – what should we be telling the parents? Prenat Diagn 30: 93–102Google Scholar
  10. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116: 402–414Google Scholar
  11. Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH (2011) Contribution of ductus venosus Doppler in first-trimester screening for major cardiac defects. Fetal Diagn Ther 29: 127–134Google Scholar
  12. Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH (2006) Nasal bone in first–trimester screening for trisomy 21. Am J Obstet Gynecol 195: 109–114Google Scholar
  13. Cuckle HS (2011) Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 32 (Suppl): S42–S48Google Scholar
  14. Cuckle HS, Wald NJ, Thompson SG (1987) Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387–402Google Scholar
  15. Cuckle H, Benn P, Wright D (2005) Down syndrome screening in the first and/ or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 29: 252–257Google Scholar
  16. De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A (2012) Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 307: 2286–2294Google Scholar
  17. De Souza E, Halliday J, Chan A, Bower C, Morris JK (2009) Recurrence risks for trisomies 13, 18 and 21. Am J Med Genet A 149: 2716–2722Google Scholar
  18. Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337: a2547Google Scholar
  19. Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH (2011) Maternal serum visfatin at 11–13 weeks of gestation in gestational diabetes mellitus. Clin Chem 57: 609–613Google Scholar
  20. Flenady V, Koopmans L, Middleton P, Frøen JF, Smith GC, Gibbons K, Coory M, Gordon A, Ellwood D, McIntyre HD, Fretts R, Ezzati M (2011) Major risk factors for stillbirth in high-income countries: a systematic review and metaanalysis. Lancet 377: 1331–1340Google Scholar
  21. Fuchs IB, Muller H, Abdul-Khaliq H, Harder T, Dudenhausen JW, Henrich W (2007) Immediate and long-term outcomes in children with prenatal diagnosis of selected isolated congenital heart defects. Ultrasound Obstet Gynecol 29: 38–43Google Scholar
  22. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH (2017) Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol doi: 10.1002/uog.17484. [Epub ahead of print]
  23. Greco E, Lange A, Ushakov F, Calvo JR, Nicolaides KH (2011) Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks. Prenat Diagn 31: 84–89Google Scholar
  24. Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study. BMJ 318: 81–85Google Scholar
  25. Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH (2006) Relation between increased fetal nuchal translucency, thickness and chromosomal defects. Obstet Gynecol 107: 6–10Google Scholar
  26. Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH (2007) Discordance in nuchal translucency, thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 29: 527–532Google Scholar
  27. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH (2008a) Screening for trisomy 21 by maternal age fetal nuchal translucency thickness free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 31: 618–624Google Scholar
  28. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008b) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493–502Google Scholar
  29. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH (2008c) Screening for trisomies 21 18 and 13 by maternal age fetal nuchal translucency fetal heart rate free beta-HCG and pregnancy-associated plasma protein-A. Hum Reprod 23: 1968–1975Google Scholar
  30. Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH (2009a) Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33: 259–264Google Scholar
  31. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009b) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34: 14–18Google Scholar
  32. Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH (2009c) Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 33: 18–22Google Scholar
  33. Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH (2009d) Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 33: 657–664Google Scholar
  34. Kagan KO, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH (2010) The 11–13- week scan: diagnosis and outcome of holoprosencephaly exomphalos and megacystis. Ultrasound Obstet Gynecol 36: 10–14Google Scholar
  35. Kagan KO, Eiben B, Kozlowski P (2014) Kombiniertes Ersttrimesterscreening und zellfreie fetale DNA – »Next Generation Screening«. Ultraschall Med 35: 229–236Google Scholar
  36. Kagan KO, Schmid M, Hoopmann M, Wagner P, Abele H (2015a) Screening performance and costs of different strategies in prenatal screening for trisomy 21. Geburtsh Frauenheilk 75: 244–250Google Scholar
  37. Kagan KO, Wright D, Nicolaides KH (2015b) First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 45: 42–47Google Scholar
  38. Lau TK, Cheung SW, Lo PSS, Pursley AN, Chan MK, Jiang F, Zhang H, Wang W, Jong LFJ, Yuen OKC, Chan HYC, Chan WSK, Choy KW (2014) Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. Ultrasound Obstet Gynecol 43: 254–264Google Scholar
  39. Lo YM, Corbetta N, Chamberlain PF, Redman CW, Sargent IL, Rai V, et al (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350: 485–487Google Scholar
  40. Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K (2011) A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 37: 38–47Google Scholar
  41. Maiz N, Kagan KO, Milovanovic Z, Celik E, Nicolaides KH (2008) Learning curve for Doppler assessment of ductus venosus flow at 11 + 0 to 13 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 31: 503–506Google Scholar
  42. Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH (2009) Ductus venosus Doppler in screening for trisomies 21,18 and 13 and Turner syndrome at 11–13 weeks of gestation. Ultrasound Obstet Gynecol 33: 512–517Google Scholar
  43. Maiz N, Wright D, Ferreira AFA, Syngelaki A, Nicolaides KH (2012) A Mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11–13 weeks gestation. Fetal Diagn Ther 31: 221–229Google Scholar
  44. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D’Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium (2005) First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 353: 2001–2011Google Scholar
  45. Matias A, Montenegro N, Loureiro T, Cunha M, Duarte S, Freitas D, Severo M (2010) Screening for twin-twin transfusion syndrome at 11–14 weeks of pregnancy: the key role of ductus venosus blood flow assessment. Ultrasound Obstet Gynecol 35: 142–148Google Scholar
  46. Merz E, Thode C, Alkier A, Eiben B, Hackelöer BJ, Hansmann M, Huesgen G, Kozlowski P, Pruggmaier M, Wellek S (2008) A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in der Medizin 29: 639–645Google Scholar
  47. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ (2016) Pre-eclampsia. Lancet 387: 999–1011Google Scholar
  48. Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH (2006) Cystic hygromas nuchal edema and nuchal translucency at 11–14 weeks of gestation. Obstet Gynecol 107: 678–683Google Scholar
  49. Morgan S, Delbarre A, Ward P (2013) Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. Ultrasound Obstet Gynecol 41: 526–529Google Scholar
  50. Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH (2011) Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 31: 135–141Google Scholar
  51. Nicolaides KH (2003) Screening for chromosomal defects. Ultrasound Obstet Gynecol 21: 313–321Google Scholar
  52. Nicolaides KH (2011) A model for a new pyramid of prenatal care based on the 11 to 13 weeks’ assessment. Prenat Diagn 31: 3–6Google Scholar
  53. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated twostage first-trimester screening. Ultrasound Obstet Gynecol 25: 221–226Google Scholar
  54. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Hollemon D, Cuckle H, Musci TJ, Wapner RJ (2015) Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 372: 1589–1597Google Scholar
  55. Papatheodorou SI, Evangelou E, Makrydimas G, Ioannidis J (2011) First-trimester ductus venosus screening for cardiac defects: a meta-analysis. BJOG 118: 1438–1445Google Scholar
  56. Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, Leung C, Saaid R, Rawashdeh H, Ogle R, Hyett J (2015) Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol 46: 419–423Google Scholar
  57. Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH (2011) Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol 117: 1384–1391Google Scholar
  58. Persico N, Moratalla J, Lombardi CM, Zidere V, Allan L, Nicolaides KH (2011) Fetal echocardiography at 11–13 weeks by transabdominal high-frequency ultrasound. Ultrasound Obstet Gynecol 37: 296–301Google Scholar
  59. Plasencia W, Garcia R, Pereira S, Akolekar R, Nicolaides KH (2011) Criteria for screening and diagnosis of gestational diabetes mellitus in the first trimester of pregnancy. Fetal Diagn Ther 30: 108–15Google Scholar
  60. Poon LC, Nicolaides KH (2014) First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn 34: 618–627Google Scholar
  61. Poon LC, v Kametas NA, Pandeva I, Valencia C, Nicolaides KH (2008) Mean arterial pressure at 11 (+0) to 13 (+6) weeks in the prediction of preeclampsia.Hypertension 51: 1027–1033Google Scholar
  62. Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH (2011) Firsttrimester prediction of macrosomia. Fetal Diagn Ther 29: 139–147Google Scholar
  63. Prats P, Rodríguez I, Comas C, Puerto B (2014) Systematic review of screening for trisomy 21 in twin pregnancies in first trimester combining nuchal translucency and biochemical markers: a meta-analysis. Prenat Diagn 34: 1077–1083Google Scholar
  64. Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E (2013) Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 41: 491–499Google Scholar
  65. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH (2017a) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med doi: 10.1056/NEJMoa1704559. [Epub ahead of print]
  66. Rolnik DL, Wright D, Poon LC, Syngelaki A, O’Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH (2017b) ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol doi: 10.1002/uog.18816. [Epub ahead of print]
  67. Salomon LJ, Alfirevic Z, Audibert F, Kagan KO, Paladini D, Yeo G, Raine-Fenning N, on behalf of the ISUOG Clinical Standards Committee (2014) ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound Obstet Gynecol 44: 122–123Google Scholar
  68. Scazzocchio E, Figueras F (2011) Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 23: 65–71Google Scholar
  69. Schmid M, Klaritsch P, Arzt W, Burkhardt T, Duba HC, Häusler M, Hafner E, Lang U, Pertl B, Speicher M, Steiner H, Tercanli S, Merz E, Heling KS, Eiben B (2015) Cell-Free DNA testing for fetal chromosomal anomalies in clinical practice: Austrian-German-Swiss recommendations for non-invasive prenatal tests (NIPT). Ultraschall Med 36: 507–510Google Scholar
  70. Schulte-Vallentin M, Schindler H (1992) Non-echogenic nuchal oedema as a marker in trisomy 21 screening. Lancet 25: 8800Google Scholar
  71. Senat MV, Frydman R (2007) Increased nuchal translucency with normal karyotype. Gynecol Obstet Fertil 35: 507–515Google Scholar
  72. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343–346Google Scholar
  73. Snijders RJ, Sebire NJ, Nicolaides KH (1995) Maternal age and gestational agespecific risk for chromosomal defects. Fetal Diagn Ther 10: 356–367Google Scholar
  74. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH (2005) Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192: 1005–1021Google Scholar
  75. Spencer K, Nicolaides KH (2003) Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 110: 276–280Google Scholar
  76. Spencer K, Cowans NJ, Avgidou K, Nicolaides KH (2006) First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 28: 637–643Google Scholar
  77. Spencer K, Kagan KO, Nicolaides KH (2008) Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 28: 49–52Google Scholar
  78. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH (2011) Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 31: 90–102Google Scholar
  79. Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R, Nicolaides KH (2015) First-trimester screening for gestational diabetes mellitus based on maternal characteristics and history. Fetal Diagn Ther 38: 14–21Google Scholar
  80. Szabo J, Gellen J (1990) Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester Lancet 336: 1133Google Scholar
  81. Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 27: 1–7Google Scholar
  82. Tegnander E, Williams W, Johansen OJ, Blaas HG, Eik-Nes SH (2006) Prenatal detection of heart defects in a non-selected population of 30,149 fetuses – detection rates and outcome. Ultrasound Obstet Gynecol 27: 252–265Google Scholar
  83. The Fetal Medicine Foundation (2015). Nuchal translucency scan. https://fetalmedicine.org/training-n-certification/certificates-of-competence/nuchal-translucency-scan (Zugegriffen 14. Juni 2017)
  84. Wagner P, Sonek J, Hoopmann M, Abele H, Kagan KO (2016) First-trimester screening for trisomy 18, 13, triploidy and Turner syndrome by a detailed early anomaly scan. Ultrasound Obstet Gynecol 48: 446–451Google Scholar
  85. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM (2003) First and second trimester antenatal screening for Down’s syndrome: the results of the Serum Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56–104Google Scholar
  86. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH (2008) A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31: 376–383Google Scholar
  87. Wright D, Bradbury I, Malone F, D’Alton M, Summers A, Huang T, Ball S, Baker A, Nix B, Aitken D, Crossley J, Cuckle H, Spencer K (2010a) Cross-trimester repeated measures testing for Down’s syndrome screening: an assessment. Health Technol Assess 14: 1–80Google Scholar
  88. Wright D, Spencer K, Kagan KK, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH (2010b) First-trimester combined screening for trisomy 21 at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 36: 404–411Google Scholar
  89. Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH (2011a) First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies. Fetal Diagn Ther 30: 194–202Google Scholar
  90. Wright D, Syngelaki A, Staboulidou I, Cruz Jde J, Nicolaides KH (2011b) Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenat Diagn 31: 16–21Google Scholar
  91. Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH (2012) A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 32: 171–178Google Scholar
  92. Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH (2014) First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther 35: 118–126Google Scholar
  93. Wright D, Gallo DM, Pugliese SG, Casanova C, Nicolaides KH (2016) Contingent screening for preterm preeclampsia. Ultrasound Obstet Gynecol 47: 554–559Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2018

Authors and Affiliations

  1. 1.Universitäts-Frauenklinik TübingenTübingenDeutschland
  2. 2.Universitätsklinikum TübingenFrauenklinikTübingenDeutschland

Personalised recommendations